Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 2.274
Filter
1.
J Obstet Gynaecol Res ; 50(10): 1795-1800, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39246055

ABSTRACT

AIM: To determine the role of preoperative MRI in the diagnosis and treatment of patients with granulosa cell tumors (GCTs) of the ovary. MATERIALS AND METHODS: Twenty-four patients who were operated on between 2018 and 2022 and who were pathologically diagnosed with GHT and met the inclusion criteria were retrospectively examined. The findings were compared with the patients' demographic data, symptoms, surgical findings (laterality, stage, lymph node involvement, endometrial pathology, tumor size), and CA-125 levels. RESULTS: The final cohort included 24 patients with a mean age of 54.71 ± 16.52. All the patients had the pathological diagnosis of adult type GCT. In the morphological evaluation, the most common finding was a solid-cystic mixed type (14 patients, 58.3%), while intratumoral hemorrhage signal was observed in 10 patients (41.7%). In the majority of cases (91.7%), the mass showed regular contours. The honeycomb/Swiss cheese sign was detected in 54.2% of the cases. When the T1 and T2 signal of the solid component of the mass were examined relative to the myometrium, the majority of GCTs appeared isointense on both sequences (83.3% and 62.5%, respectively). The mean ADC value of the solid component obtained from diffusion-weighted imaging was 0.78 ± 0.15 × 10-3. Pelvic fluid was observed in 41.7% of the cases. The average endometrial thickness was 9.74 ± 6.43 mm. Thickened endometrium more than 9 mm was observed in 9 out of the remaining 21 patients (42.9%). CONCLUSION: Understanding the key imaging features for GCTs plays an essential role in the diagnosis and guiding the treatment effectively.


Subject(s)
Granulosa Cell Tumor , Magnetic Resonance Imaging , Ovarian Neoplasms , Humans , Female , Granulosa Cell Tumor/diagnostic imaging , Granulosa Cell Tumor/pathology , Granulosa Cell Tumor/surgery , Middle Aged , Adult , Retrospective Studies , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/pathology , Aged , Prognosis
3.
Arch Gynecol Obstet ; 310(4): 2167-2171, 2024 10.
Article in English | MEDLINE | ID: mdl-39214901

ABSTRACT

INTRODUCTION: We aimed to demonstrate the sensitivity of frozen section for patients with adult granulosa cell tumor (AGCT) and analyze the clinico-pathological factors that may be associated with sensitivity. MATERIAL METHODS: This is a multicenter study including data of 10 Gynecological Oncology Departments. Frozen-section results of patients who had ovarian AGCT at the final pathology report were retrospectively analyzed. The relation between clinico-pathological characteristics such as age, tumor size, Ca-125 level, presence of ascites, omental metastasis, menopausal status and peritoneal cytology, and the sensitivity of frozen section in patients with AGCT were evaluated. The sensitivity of frozen section diagnosis was determined by comparing the frozen section result with the final pathological diagnosis. RESULTS: Frozen section results of 274 patients with AGCT were obtained. The median age of the patients was 52 years (range, 17-82 years). Totally, 144 (52.7%, n = 273) patients were postmenopausal. The median tumour size was 90 mm (range, 9-700 mm). The median preoperative Ca-125 level was 23 IU/mL (range, 2-995 IU/mL). The sensitivity of frozen section for detecting AGCT was 76.3%. Any association between the sensitivity of frozen section and menopausal status, presence of ascites, positive cytology, omental metastasis, tumor size, Ca-125 level, age could not be shown. CONCLUSION: It is important to know the diagnosis of AGCT intraoperatively, and we demonstrated the sensitivity of frozen-section for these tumors as 76.3%.


Subject(s)
CA-125 Antigen , Frozen Sections , Granulosa Cell Tumor , Ovarian Neoplasms , Sensitivity and Specificity , Humans , Female , Granulosa Cell Tumor/pathology , Granulosa Cell Tumor/blood , Adult , Middle Aged , Aged , Retrospective Studies , Adolescent , Young Adult , Aged, 80 and over , Ovarian Neoplasms/pathology , Ovarian Neoplasms/blood , CA-125 Antigen/blood , Ascites/pathology
4.
PLoS One ; 19(8): e0308168, 2024.
Article in English | MEDLINE | ID: mdl-39110703

ABSTRACT

The ovarian KGN granulosa-like tumour cell line is commonly used as a model for human granulosa cells, especially since it produces steroid hormones. To explore this further, we identified genes that were differentially expressed by KGN cells compared to primary human granulosa cells using three public RNA sequence datasets. Of significance, we identified that the expression of the antioxidant gene TXNRD1 (thioredoxin reductase 1) was extremely high in KGN cells. This is ominous since cytochrome P450 enzymes leak electrons and produce reactive oxygen species during the biosynthesis of steroid hormones. Gene Ontology (GO) analysis identified steroid biosynthetic and cholesterol metabolic processes were more active in primary granulosa cells, whilst in KGN cells, DNA processing, chromosome segregation and kinetochore pathways were more prominent. Expression of cytochrome P450 cholesterol side-chain cleavage (CYP11A1) and cytochrome P450 aromatase (CYP19A1), which are important for the biosynthesis of the steroid hormones progesterone and oestrogen, plus their electron transport chain members (FDXR, FDX1, POR) were measured in cultured KGN cells. KGN cells were treated with 1 mM dibutyryl cAMP (dbcAMP) or 10 µM forskolin, with or without siRNA knockdown of TXNRD1. We also examined expression of antioxidant genes, H2O2 production by Amplex Red assay and DNA damage by γH2Ax staining. Significant increases in CYP11A1 and CYP19A1 were observed by either dbcAMP or forskolin treatments. However, no significant changes in H2O2 levels or DNA damage were found. Knockdown of expression of TXNRD1 by siRNA blocked the stimulation of expression of CYP11A1 and CYP19A1 by dbcAMP. Thus, with TXNRD1 playing such a pivotal role in steroidogenesis in the KGN cells and it being so highly overexpressed, we conclude that KGN cells might not be the most appropriate model of primary granulosa cells for studying the interplay between ovarian steroidogenesis, reactive oxygen species and antioxidants.


Subject(s)
Antioxidants , Aromatase , Cholesterol Side-Chain Cleavage Enzyme , Granulosa Cells , Humans , Female , Antioxidants/metabolism , Aromatase/genetics , Aromatase/metabolism , Cell Line, Tumor , Granulosa Cells/metabolism , Cholesterol Side-Chain Cleavage Enzyme/genetics , Cholesterol Side-Chain Cleavage Enzyme/metabolism , Thioredoxin Reductase 1/metabolism , Thioredoxin Reductase 1/genetics , Gene Expression Regulation, Neoplastic , Granulosa Cell Tumor/genetics , Granulosa Cell Tumor/metabolism , Granulosa Cell Tumor/pathology , Steroids/biosynthesis , Progesterone/metabolism , Ovarian Neoplasms/genetics , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology
5.
Pathology ; 56(6): 842-853, 2024 Oct.
Article in English | MEDLINE | ID: mdl-38977384

ABSTRACT

Ovarian sex cord-stromal tumours (SCSTs) present diagnostic difficulties during frozen section (FS) consultations due to their diverse morphology. This study aimed to evaluate the accuracy of FS evaluation of SCSTs in our institution, as well as to examine the reasons leading to incorrect FS diagnosis. Cases mimicking SCSTs and diagnosed as such during FS were also highlighted. We analysed 121 ovarian SCST cases and their mimics which underwent FS consultations over a 10-year period, to evaluate FS accuracy, reasons for deferrals and discrepancies. FS diagnoses were concordant, deferred and discrepant compared to the final diagnosis in 50 (41.3%), 39 (32.2%) and 32 (26.5%) cases, respectively. Major discrepancies (9/121, 7.4%) were mostly related to the diagnosis of adult granulosa cell tumour (AGCT). A fibromatous AGCT was misinterpreted as fibroma on FS, while a cystic AGCT was called a benign cyst. Conversely, a mesonephric-like adenocarcinoma, a sertoliform endometrioid carcinoma and a thecoma were misinterpreted as AGCT on FS. Another discrepant case was a Krukenberg tumour with prominent fibromatous stroma in which malignant signet ring cells were overlooked and misinterpreted as fibroma. Minor discrepancies were primarily associated with fibroma (21/23, 91.3%), wherein minor but potentially impactful details such as cellular fibroma and mitotically active cellular fibroma were missed due to sampling issues and misinterpretation as leiomyoma. FS evaluation for ovarian SCSTs demonstrated an overall accuracy of 78.5%, 81.0% and 81.8% for benign, uncertain/low malignant potential and malignant categories, respectively. There was no FS-related adverse clinical impact in all cases with available follow-up information (120/121 cases). Intraoperative FS evaluation of ovarian SCSTs is challenging. A small number of cases were misinterpreted, with AGCTs being the primary group where errors occur. Awareness of common diagnostic pitfalls and difficulties, alongside application of a stepwise approach, including (1) obtaining comprehensive clinical information, (2) thorough macroscopic examination and directed sampling, (3) meticulous microscopic examination with consideration of pitfalls and mimics, (4) effective communication with surgeons in difficult cases, and (5) consultation of subspecialty colleagues in challenging cases, will enhance pathologists' reporting accuracy and management of such cases in the future.


Subject(s)
Frozen Sections , Granulosa Cell Tumor , Ovarian Neoplasms , Sex Cord-Gonadal Stromal Tumors , Humans , Female , Sex Cord-Gonadal Stromal Tumors/pathology , Sex Cord-Gonadal Stromal Tumors/diagnosis , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/pathology , Adult , Middle Aged , Diagnosis, Differential , Granulosa Cell Tumor/pathology , Granulosa Cell Tumor/diagnosis , Aged , Diagnostic Errors , Young Adult , Fibroma/diagnosis , Fibroma/pathology , Adolescent , Aged, 80 and over , Thecoma/diagnosis , Thecoma/pathology
6.
Gynecol Oncol ; 189: 30-36, 2024 Oct.
Article in English | MEDLINE | ID: mdl-38991472

ABSTRACT

OBJECTIVE: To determine the safety and efficacy of the oral progesterone antagonist onapristone extended release (onapristone-XR) in patients with recurrent progesterone receptor (PR)-positive adult-type granulosa cell tumor (aGCT), low-grade serous ovarian cancer (LGSOC), or endometrioid endometrial cancer (EEC). METHODS: This single-institution phase II study included patients with PR-positive aGCT, LGSOC, or EEC who received ≥1 prior line of chemotherapy. Patients were enrolled from 5/2019-5/2020. PR status was evaluated via immunohistochemistry. Eligible patients had PR expression ≥1% on tissue collected within 3 years of enrollment. Patients received 50 mg of onapristone-XR twice daily until disease progression or treatment discontinuation. Adverse events were graded by Common Terminology Criteria for Adverse Events version 5.0. The primary endpoint was overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors 1.1. Secondary endpoints were response duration, clinical benefit rate (CBR), and safety. RESULTS: Five patients with LGSOC and 1 with EEC enrolled, but both cohorts closed early due to slow accrual. Fourteen patients with aGCT enrolled and completed stage 1 accrual. No responses were observed. Four patients with LGSOC were evaluable, with median PFS of 4.4 months (range, 1.8-NE) and CBR of 50% (range, 6.8%-93.2%). All 14 patients with aGCT were evaluable, with median PFS of 2.8 months (range, 1.6-4.9), 6-month PFS rate of 21.4% (range, 5.2%-44.8%), 12-month PFS rate of 14.3% (range, 2.3%-36.6%), and a CBR of 35.7% (range, 12.8%-64.9%). CONCLUSIONS: The study did not meet its primary endpoint. While onapristone-XR was well tolerated in all 3 arms, no objective responses were observed.


Subject(s)
Carcinoma, Endometrioid , Endometrial Neoplasms , Granulosa Cell Tumor , Neoplasm Recurrence, Local , Ovarian Neoplasms , Receptors, Progesterone , Humans , Female , Middle Aged , Aged , Receptors, Progesterone/metabolism , Endometrial Neoplasms/drug therapy , Endometrial Neoplasms/pathology , Neoplasm Recurrence, Local/drug therapy , Carcinoma, Endometrioid/drug therapy , Carcinoma, Endometrioid/pathology , Carcinoma, Endometrioid/metabolism , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/pathology , Ovarian Neoplasms/metabolism , Granulosa Cell Tumor/drug therapy , Granulosa Cell Tumor/metabolism , Granulosa Cell Tumor/pathology , Adult , Gonanes/administration & dosage , Gonanes/adverse effects , Delayed-Action Preparations/administration & dosage , Aged, 80 and over , Administration, Oral , Cystadenocarcinoma, Serous/drug therapy , Cystadenocarcinoma, Serous/pathology , Cystadenocarcinoma, Serous/metabolism
8.
BMJ Case Rep ; 17(7)2024 Jul 16.
Article in English | MEDLINE | ID: mdl-39013625

ABSTRACT

This case report delves into the diagnostic intricacies and clinical management of adult granulosa cell tumour (AGCT) in a woman in her 50s, presenting with pain abdomen. Initial imaging investigations like ultrasound suggested diagnosis of benign cystadenoma. Further MRI revealed a large well-defined multiloculated lesion so a diagnosis of neoplastic aetiology/likely mucinous cystadenocarcinoma was offered. However, the definitive diagnosis was established through meticulous histopathological examination, revealing characteristic features of AGCT, a rare ovarian neoplasm. The case underscores the diagnostic challenges posed by AGCT, the importance of integrating clinical, radiological and histopathological data, and the necessity for a multidisciplinary approach for accurate diagnosis and optimal patient management.


Subject(s)
Granulosa Cell Tumor , Ovarian Neoplasms , Humans , Female , Granulosa Cell Tumor/diagnosis , Granulosa Cell Tumor/pathology , Granulosa Cell Tumor/diagnostic imaging , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/pathology , Middle Aged , Diagnosis, Differential , Magnetic Resonance Imaging , Cystadenocarcinoma, Mucinous/diagnosis , Cystadenocarcinoma, Mucinous/pathology , Cystadenocarcinoma, Mucinous/diagnostic imaging
9.
Virchows Arch ; 485(3): 427-437, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38904760

ABSTRACT

The current knowledge about the immunohistochemical features of adult granulosa cell tumor (AGCT) is mostly limited to the "traditional" immunohistochemical markers of sex cord differentiation, such as inhibin, calretinin, FOXL2, SF1, and CD99. Knowledge about the immunohistochemical markers possibly used for predictive purpose is limited. In our study, we focused on the immunohistochemical examination of 290 cases of AGCT classified based on strict diagnostic criteria, including molecular testing. The antibodies used included 12 of the "diagnostic" antibodies already examined in previous studies, 10 antibodies whose expression has not yet been examined in AGCT, and 7 antibodies with possible predictive significance, including the expression of HER2, PD-L1, CTLA4, and 4 mismatch repair (MMR) proteins. The results of our study showed expression of FOXL2, SF1, CD99, inhibin A, calretinin, ER, PR, AR, CKAE1/3, and CAIX in 98%, 100%, 90%, 78%, 45%, 41%, 94%, 82%, 26%, and 9% of AGCT, respectively. GATA3, SATB2, napsin A, MUC4, TTF1, and CD44 were all negative. PTEN showed a loss of expression in 71% of cases and DPC4 in 4% of cases. The aberrant staining pattern (overexpression) of p53 was found in 1% (3/268) of cases, 2 primary tumors, and 1 recurrent case. Concerning the predictive markers, the results of our study showed that AGCT is microsatellite stable, do not express PD-L1, and are HER2 negative. The CTLA4 expression was found in almost 70% of AGCT tumor cells.


Subject(s)
Biomarkers, Tumor , Granulosa Cell Tumor , Immunohistochemistry , Ovarian Neoplasms , Humans , Biomarkers, Tumor/analysis , Female , Granulosa Cell Tumor/pathology , Granulosa Cell Tumor/metabolism , Ovarian Neoplasms/pathology , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/diagnosis , Adult , Middle Aged
10.
Urology ; 190: e21-e23, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38897318

ABSTRACT

Adult-type Granulosa cell tumor of the testis is a rare subtype of sex cord-stromal tumors, with fewer than 100 cases reported. The typical clinical presentation is an asymptomatic, painless testicular mass. We report a case of a 16-year-old male with adult-type testicular Granulosa cell tumor who presented with a palpable, painless right testicular mass, and subsequently underwent right inguinal radical orchiectomy. This report contributes to the growing body of literature regarding this rare diagnosis, furthering our understanding of clinical, imaging, and histological findings of its presentation.


Subject(s)
Granulosa Cell Tumor , Testicular Neoplasms , Humans , Granulosa Cell Tumor/pathology , Granulosa Cell Tumor/surgery , Granulosa Cell Tumor/diagnosis , Granulosa Cell Tumor/diagnostic imaging , Testicular Neoplasms/pathology , Testicular Neoplasms/surgery , Testicular Neoplasms/diagnosis , Male , Adolescent , Orchiectomy/methods
11.
Cancer Med ; 13(12): e7340, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38898688

ABSTRACT

OBJECTIVE: The objective of this study was to assess the frequency of potential germline pathogenic variants that may contribute to risk of development of adult granulosa cell tumors (AGCT) given the paucity of germline testing guidelines for these patients. METHODS: This was a retrospective cross-sectional study analyzing comprehensive genomic profiling (CGP) results of AGCT with the FOXL2 p.C134W mutation submitted to Foundation Medicine between 2012 and 2022. Cases with a potential germline pathogenic variant were identified by filtering single nucleotide variants and short indels by variant allele frequency (VAF) and presence in ClinVar for select cancer susceptibility genes. Odds ratios for AGCT risk were calculated compared to a healthy population. RESULTS: Prior to analysis, 595 patients were screened and 516 with a somatic FOXL2 p.C134W mutation were included. Potential germline pathogenic variants in a DNA repair-related gene (ATM, BRCA1, BRCA2, CHEK2, PALB2, PMS2, RAD51C, or RAD51D) were found in 6.6% of FOXL2-mutated AGCT. Potential germline pathogenic CHEK2 variants were found in 3.5% (18/516) of AGCT patients, a rate that was 2.8-fold higher than Genome Aggregation Database non-cancer subjects (95% CI 1.8-4.6, p < 0.001). The founder variants p.I157T (38.9%, 7/18) and p.T367fs*15 (c.1100delC; 27.8%, 5/18) were most commonly observed. CHEK2 VAF indicated frequent loss of the wildtype copy of the gene. CONCLUSIONS: These results support ongoing utilization of genomic tumor profiling and confirmatory germline testing for potential germline pathogenic variants. Further prospective investigation into the biology of germline variants in this population is warranted.


Subject(s)
Forkhead Box Protein L2 , Genetic Predisposition to Disease , Germ-Line Mutation , Granulosa Cell Tumor , Humans , Female , Granulosa Cell Tumor/genetics , Granulosa Cell Tumor/pathology , Retrospective Studies , Middle Aged , Forkhead Box Protein L2/genetics , Cross-Sectional Studies , Adult , Aged , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Checkpoint Kinase 2/genetics , Aged, 80 and over
12.
J Ovarian Res ; 17(1): 127, 2024 Jun 19.
Article in English | MEDLINE | ID: mdl-38898511

ABSTRACT

BACKGROUND: This retrospective study aims to evaluate the clinical course and long-term outcomes of patients diagnosed with adult granulosa cell tumors (AGCT). METHODS: The study analyzed a cohort of 112 AGCT patients with a median follow-up of 87 months. Data regarding disease-free survival (DFS), overall survival (OS), recurrence rates, and prognostic factors were collected and analyzed. Surgical interventions, including lymphadenectomy and cytoreductive surgery, were assessed for their impact on outcomes. RESULTS: The study revealed favorable long-term outcomes, with a 5-year DFS of 85% and a 10-year DFS of 83%. Additionally, a 5-year OS of 100% and a 10-year OS of 96% were observed. Recurrence occurred in 13.4% of cases, with advanced stage and positive peritoneal cytology identified as independent poor prognostic factors for DFS. Lymph node involvement was rare, and routine lymphadenectomy did not improve outcomes. Conservative surgery showed comparable DFS rates to definitive surgery in early-stage disease. However, cytoreductive surgery was crucial for advanced and recurrent tumors, with complete tumor resection enhancing survival outcomes. CONCLUSION: The study underscores the importance of vigilant follow-up and individualized treatment strategies for AGCT patients. Despite the retrospective nature of the analysis, the substantial patient cohort and meticulous surgical interventions contribute valuable insights into AGCT management. Prospective multicenter studies are warranted to further elucidate prognostic factors and optimize treatment approaches for this rare malignancy.


Subject(s)
Granulosa Cell Tumor , Humans , Female , Granulosa Cell Tumor/pathology , Granulosa Cell Tumor/mortality , Granulosa Cell Tumor/surgery , Middle Aged , Adult , Retrospective Studies , Prognosis , Aged , Neoplasm Recurrence, Local , Disease-Free Survival , Treatment Outcome , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Ovarian Neoplasms/surgery , Cytoreduction Surgical Procedures , Young Adult
13.
PLoS One ; 19(6): e0303989, 2024.
Article in English | MEDLINE | ID: mdl-38875223

ABSTRACT

BACKGROUND: Identifying and describing molecular alterations in tumors has become common with the development of high-throughput sequencing. However, DNA sequencing in rare tumors, such as ovarian adult granulosa cell tumor (aGCT), often lacks statistical power due to the limited number of cases in each study. Questions regarding personalized treatment or prognostic biomarkers for recurrence or other malignancies therefore still need to be elucidated. This scoping review protocol aims to systematically map the current evidence and identify knowledge gaps regarding DNA alterations, actionable variations and prognostic biomarkers in aGCT. METHODS: This scoping review will be conducted based on Arksey and O'Malley's methodological framework and later modifications by JBI Evidence Synthesis. The protocol complies with Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews. All original publications describing molecular alterations of aGCT will be included. The search will be performed in May 2024 in the following databases: MEDLINE (Ovid), Embase (Ovid), Web of Science Core Collection and Google Scholar (100-top ranked). DISCUSSION: This scoping review will identify knowledge and gaps in the current understanding of the molecular landscape of aGCT, clinical trials on actionable variations and priorities for future research. As aGCT are rare, a possible limitation will be the small sample sizes and heterogenic study settings. SCOPING REVIEW REGISTRATION: The review protocol is registered at Open Science Framework under https://doi.org/10.17605/OSF.IO/PX4MF.


Subject(s)
Granulosa Cell Tumor , Ovarian Neoplasms , Female , Humans , Biomarkers, Tumor/genetics , Granulosa Cell Tumor/genetics , Granulosa Cell Tumor/pathology , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Systematic Reviews as Topic
15.
Int J Gynecol Pathol ; 43(5): 527-534, 2024 Sep 01.
Article in English | MEDLINE | ID: mdl-38661526

ABSTRACT

Adult granulosa cell tumors (AGCTs) are rare ovarian tumors with generally good prognosis after surgical resection; however, they do have recurrence potential. Therapeutic and management options for recurrences are currently limited, and the need for expanded adjuvant therapies is increasingly recognized. Anti-hormonal therapy is being explored as an option, which relies on the detection and assessment of hormone receptor expression (androgen, estrogen, and progesterone receptors) as a biomarker and therapeutic target. Our study identifies several clinicopathologic characteristics with significant associations for recurrence of AGCT, which were younger age, higher stage, and larger tumor size. Our study also demonstrates that androgen receptor (AR) expression may be utilized as a potential biomarker for hormonal therapy and that detection of AR expression in AGCT by immunohistochemistry (IHC) varies depending on the antibody clone used for testing. AR was detected in 95% of samples tested with antibodies derived from clone AR27. This detection rate is much higher than previously reported.


Subject(s)
Granulosa Cell Tumor , Ovarian Neoplasms , Receptors, Androgen , Receptors, Estrogen , Receptors, Progesterone , Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Biomarkers, Tumor/metabolism , Biomarkers, Tumor/analysis , Cohort Studies , Granulosa Cell Tumor/pathology , Granulosa Cell Tumor/metabolism , Granulosa Cell Tumor/diagnosis , Immunohistochemistry , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/metabolism , Ovarian Neoplasms/pathology , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/diagnosis , Receptors, Androgen/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism
16.
J Steroid Biochem Mol Biol ; 242: 106526, 2024 09.
Article in English | MEDLINE | ID: mdl-38657699

ABSTRACT

Estrogen drives the growth of some cancers, such as breast cancer, via estrogen receptor alpha (ERα). Estrogen also activates ERß, but whether ERß is expressed and has a role in different cancers is debated. The use of nonspecific antibodies has contributed to the confusion, and this review delves into ERß's controversial role in cancer and focuses on tumor expression that can be supported by non-antibody-dependent assays. We discuss its expression at the transcript level and focus on its potential role in lymphoma, granulosa cell tumors, testicular, and adrenal cancers, emphasizing recent findings and the complexities that necessitate further research.


Subject(s)
Estrogen Receptor beta , Neoplasms , Humans , Estrogen Receptor beta/metabolism , Estrogen Receptor beta/genetics , Neoplasms/metabolism , Neoplasms/genetics , Female , Animals , Male , Gene Expression Regulation, Neoplastic , Testicular Neoplasms/metabolism , Testicular Neoplasms/genetics , Testicular Neoplasms/pathology , Granulosa Cell Tumor/metabolism , Granulosa Cell Tumor/genetics , Granulosa Cell Tumor/pathology , Breast Neoplasms/metabolism , Breast Neoplasms/genetics , Adrenal Gland Neoplasms/genetics , Adrenal Gland Neoplasms/metabolism , Adrenal Gland Neoplasms/pathology , Lymphoma/metabolism , Lymphoma/genetics , Lymphoma/pathology
17.
Pan Afr Med J ; 47: 58, 2024.
Article in English | MEDLINE | ID: mdl-38646138

ABSTRACT

Granulosa cell tumor (GCT) is a rare ovarian malignancy that represents only 2-3% of all cases. There are two subtypes of GCT: juvenile/JGCT (5% of cases) and adult/AGCT (95% of cases). This study aimed to describe a series of 6 GCT cases. The 6 study patients were managed from June 2011 to November 2022 in a private oncology clinic located in Teresina (PI), Brazil. At diagnosis, the mean patient age was 47 years, and symptoms in 5 patients (83%) were pelvic pain and/or increased abdominal volume. The majority of the patients (N=4/67%) had no comorbidities or findings related to GCT on physical examination. The mean tumor size was 11 cm. Five (83%) tumors were stage Ia and one tumor (17%) was stage III. Regarding tumor subtype, 5 (83%) were AGCT and 1 (17%) was JGCT. Surgical treatment consisted of unilateral salpingo-ophorectomy in 2 patients (33%), total hysterectomy and bilateral salpingo-ophorectomy in 3 patients (50%), and cytoreduction (suboptimal) in 1 patient (17%). After a mean follow-up period of 62.7 months, 5 patients (83%) are still alive and free of disease. One (17%) died from disease progression after 126 months. In the current study, disease-free overall survival was 83%, in a mean follow-up period of 62.7 months.


Subject(s)
Granulosa Cell Tumor , Neoplasm Staging , Ovarian Neoplasms , Humans , Female , Granulosa Cell Tumor/pathology , Granulosa Cell Tumor/diagnosis , Granulosa Cell Tumor/surgery , Middle Aged , Adult , Ovarian Neoplasms/pathology , Ovarian Neoplasms/diagnosis , Brazil , Hysterectomy , Follow-Up Studies , Cytoreduction Surgical Procedures/methods , Aged , Retrospective Studies , Pelvic Pain/etiology
18.
Medicina (Kaunas) ; 60(4)2024 Mar 31.
Article in English | MEDLINE | ID: mdl-38674222

ABSTRACT

Background and Objectives: Our report contributes a unique case of a non-neural GCT occurring in an unusual location, with its development during pregnancy adding to its rarity. Materials and Methods: Granular cell tumors (GCTs), also known as Abrikossoff's tumors, are rare neoplasms of Schwann cell origin with predominantly benign behavior. We present a case of a 29-year-old female with a non-neural variant of a GCT discovered incidentally during a cesarean section, situated on the posterior surface of the rectus abdominis muscle. Results: Histologically, the tumor exhibited features consistent with a benign non-neural GCT, confirmed through an immunohistochemical analysis. Despite the atypical presentation and challenging surgical removal due to prior scarring, the patient experienced no postoperative complications and showed no signs of recurrence during follow-up. Conclusions: This case highlights the importance of considering GCTs in differential diagnoses, particularly in unusual anatomical locations, and underscores the favorable prognosis associated with timely surgical intervention.


Subject(s)
Granular Cell Tumor , Granulosa Cell Tumor , Rectus Abdominis , Humans , Female , Rectus Abdominis/pathology , Rectus Abdominis/surgery , Adult , Granular Cell Tumor/surgery , Granular Cell Tumor/diagnosis , Granular Cell Tumor/pathology , Pregnancy , Muscle Neoplasms/surgery , Muscle Neoplasms/diagnosis , Muscle Neoplasms/pathology , Cesarean Section
20.
BMC Cancer ; 24(1): 309, 2024 Mar 06.
Article in English | MEDLINE | ID: mdl-38448917

ABSTRACT

BACKGROUND: Granulosa Cell Tumors (GCT) are considered the most frequent type of sex-cord stromal tumors. These tumors constitute 3-6% of neoplasms of the ovaries. GCTs are divided into 2 types: Juvenile GCT (JGCT) and Adult GCT (AGCT). Most patients are diagnosed early in the course of the disease and tend to have a favorable prognosis. In the surgical treatment of GCT, two main factors play role in the determination of feasibility of the surgery: age and tumor stage. METHODS: A retrospective study was conducted on 65 consecutive female patients diagnosed with ovarian GCT at different hospitals across Lebanon who were referred to the National Institute of Pathology, Beirut-Lebanon, between January 2000 and January 2020. Then, they were divided according to types: adult versus juvenile type. Statistical analysis was carried out using Stata, version 16. RESULTS: The incidence of GCT in a Lebanese population was 16.2 per million per year. The mean age of the studied population was 55.6 years. AGCT was the most common with a prevalence of 91% versus 19% for JGCT. Also, inhibine (the most important immunomarker) was found in 77.2% of adult cases. High mitotic index and high tumor size which are predictors for poor prognosis were respectively 20% and 36.9%. Concerning the histopathological features, Grooved nuclei and Exner bodies were less frequently observed in juvenile type (16.7% for both) compared to adult type (36.9%). Most patients with GCT were diagnosed in the early course of disease mainly due to the manifestation of the symptoms as abdominal pain, postmenopausal bleeding or intermenstrual bleeding, and the good diagnosis and screening practices in Lebanon. Regarding the recurrent cases, a significant correlation with high mitotic index (76.9%), high tumor size (92.3%) and advanced stage (46% for stage 3 and 46% for stage 4) was found with a p < 0.05. CONCLUSIONS: The incidence of GCT in the Lebanese population is 16.2 per million per year. The majority of patients with GCT in Lebanon are of Adult type representing around 90% of cases. Older age, high mitotic index and big tumor size are predictors for poor outcomes.


Subject(s)
Granulosa Cell Tumor , Adult , Humans , Female , Middle Aged , Granulosa Cell Tumor/epidemiology , Lebanon/epidemiology , Retrospective Studies , Abdominal Pain , Cell Membrane
SELECTION OF CITATIONS
SEARCH DETAIL